Licensing opportunity: ASF-1096 for cutaneous lupus erythematosus

ASF-1096 is a topically administered anti-inflammatory and immunomodulating substance for the treatment of cutaneous forms of lupus erythematosus, especially discoid lupus.

Based on a unique mechanism of action and a favourable safety profile, ASF-1096 is a promising alternative to existing treatments and may be the first truly effective treatment for discoid lupus.

ASF-1096 is covered by pending and granted patents with expiry in 2026.

Seeking partners for co-development.